Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group.

N Engl J Med. 2001 Sep 20;345(12):870-8.

2.

[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].

Parving HH, Lehnert H, Brøchner-Mortensen J, Gomis R, Andersen S, Arner P.

Ugeskr Laeger. 2001 Oct 1;163(40):5519-24. Danish.

PMID:
11601118
3.

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group.

N Engl J Med. 2001 Sep 20;345(12):851-60.

4.

Treatment of diabetic nephropathy with angiotensin II receptor antagonist.

Lewis EJ, Lewis JB.

Clin Exp Nephrol. 2003 Mar;7(1):1-8. Review.

PMID:
14586737
5.

Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.

Croom KF, Curran MP, Goa KL, Perry CM.

Drugs. 2004;64(9):999-1028. Review.

PMID:
15101793
6.

Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.

Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ; Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group.

Ann Intern Med. 2003 Apr 1;138(7):542-9.

PMID:
12667024
7.

Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-controlled crossover study.

Sasso FC, Carbonara O, Persico M, Iafusco D, Salvatore T, D'Ambrosio R, Torella R, Cozzolino D.

Diabetes Care. 2002 Nov;25(11):1909-13.

PMID:
12401731
8.

A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.

Palmer AJ, Valentine WJ, Tucker DM, Ray JA, Roze S, Annemans L, Lapuerta P, Chen R, Gabriel S, Carita P, Rodby RA, de Zeeuw D, Parving HH, Laville M.

Curr Med Res Opin. 2006 Nov;22(11):2095-100.

PMID:
17076969
9.

A clinical trial in type 2 diabetic nephropathy.

Lewis EJ, Hunsicker LG, Rodby RA; Collaborative Study Group.

Am J Kidney Dis. 2001 Oct;38(4 Suppl 1):S191-4.

PMID:
11576953
10.

The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.

Rodby RA, Rohde RD, Clarke WR, Hunsicker LG, Anzalone DA, Atkins RC, Ritz E, Lewis EJ.

Nephrol Dial Transplant. 2000 Apr;15(4):487-97.

11.

Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria.

Rossing K, Schjoedt KJ, Jensen BR, Boomsma F, Parving HH.

Kidney Int. 2005 Sep;68(3):1190-8.

12.
13.

Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria.

Andersen S, Bröchner-Mortensen J, Parving HH; Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria Study Group.

Diabetes Care. 2003 Dec;26(12):3296-302.

PMID:
14633817
16.

Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.

Fernandez Juarez G, Luño J, Barrio V, de Vinuesa SG, Praga M, Goicoechea M, Cachofeiro V, Nieto J, Fernández Vega F, Tato A, Gutierrez E; PRONEDI Study Group.

Am J Kidney Dis. 2013 Feb;61(2):211-8. doi: 10.1053/j.ajkd.2012.07.011. Epub 2012 Aug 29.

PMID:
22939518
17.

Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis.

Palmer AJ, Valentine WJ, Ray JA.

Int J Clin Pract. 2007 Oct;61(10):1626-33. Review.

PMID:
17877649
19.

Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.

Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH.

Kidney Int. 2003 May;63(5):1874-80.

20.

Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective.

Coyle D, Rodby R, Soroka S, Levin A, Muirhead N, de Cotret PR, Chen R, Palmer A.

Clin Ther. 2007 Jul;29(7):1508-23.

PMID:
17825702
Items per page

Supplemental Content

Write to the Help Desk